Trastuzumab deruxtecan is an HER 2-directed antibody-drug conjugate with ability to cross the blood-tumor barrier and activity on brain metastases. To test the activity of new drugs patient-derived xenografts (PDX) models from human brain metastases and phase 0 and window of opportunity trials are of utmost importance.

Brain metastasis from HER2-positive breast cancer: an evolving landscape

Soffietti, Riccardo
First
;
Pellerino, Alessia
Last
2023-01-01

Abstract

Trastuzumab deruxtecan is an HER 2-directed antibody-drug conjugate with ability to cross the blood-tumor barrier and activity on brain metastases. To test the activity of new drugs patient-derived xenografts (PDX) models from human brain metastases and phase 0 and window of opportunity trials are of utmost importance.
2023
29
1
8
10
Soffietti, Riccardo; Pellerino, Alessia
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1877963
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact